Live federal data · NADAC weekly · Part D CY24

Rivaroxaban Apixaban

Rivaroxaban vs Apixaban — $41.72B of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated 14 Jul 2026

NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Factor Xa Inhibitor

Rivaroxaban

Brand: XARELTO

First FDA approval: 2011-07-01

Factor Xa Inhibitor

Apixaban

Brand: ELIQUIS

First FDA approval: 2012-12-28

Lowest NADACAcquisition cost floor across all NDCs

$0.797Per unit

$5.51Per unit

Average NADACAcross all dosage forms and strengths

$7.57Up to $19.56

$5.52Up to $5.52

Generic manufacturersActive ANDA holders — FDA Orange Book

1758 total ANDAs filed

24 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$9.48BFull year

$32.24BFull year

Part D claims (CY24)Total fills, all strengths

10.0M2.5M beneficiaries

36.8M8.4M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$951Per claim, all NDCs

$875Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

1Minimal friction

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

62Limited friction

18Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes17 manufacturers

Yes2 manufacturers